A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.
Håkan Mellstedt(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Carina Norström(Kancera (Sweden)), Thomas Olin(Kancera (Sweden)), Anders Österborg(Karolinska University Hospital), Charlotte Lofberg(Kancera (Sweden)), Amir Hossein Daneshmanesh(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Jan Vågberg(Kancera (Sweden)), Elisabeth Olsson(Karolinska Institutet), Styrbjörn Byström(Karolinska Institutet), Johan Schultz(Kancera (Sweden)), Martin Norin(Kancera (Sweden)), Salam Khan
Cited by 4
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312